References
- Anttila M, Penttila J, Helminen A, Vuorilehto L, Scheinin H. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. British Journal of Clinical Pharmacology 2003; 56: 691–693
- Dyck JB, Maze M, Haack C, Vuorilehto L, Shafer SL. The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology 1993; 78: 813–820
- Penttila J, Helminen A, Anttila M, Hinkka S, Scheinin H. Cardiovascular and parasympathetic effects of dexmedetomidine in healthy subjects. Canadian Journal of Physiology and Pharmacology 2004; 82: 359–362
- Tobias JD, Berkenbosch JW, Russo P. Additional experience with dexmedetomidine in pediatric patients. Southern Medical Journal 2003; 96: 871–875
- Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs 2000; 59: 263–268, discussion 269–270
- Weinbroum AA, Ben-Abraham R. Dextromethorphan and dexmedetomidine: New agents for the control of perioperative pain. European Journal of Surgery 2001; 167: 563–569
- Tobias JD, Berkenbosch JW. Sedation during mechanical ventilation in infants and children: Dexmedetomidine versus midazolam. Southern Medical Journal 2004; 97: 451–455
- Venn RM, Grounds RM. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: Patient and clinician perceptions. British Journal of Anaesthesiology 2001; 87: 684–690
- Prielipp RC, Wall MH, Tobin JR, Groban L, Cannon MA, Fahey FH, Gage HD, Stump DA, James RL, Bennett J, et al. Dexmedetomidine-induced sedation in volunteers decreases regional and global cerebral blood flow. Anesthesia and Analgesia 2002; 95: 1052–1059
- Martin E, Ramsay G, Mantz J, Sum-Ping ST. The role of the alpha2-adrenoceptor agonist dexmedetomidine in postsurgical sedation in the intensive care unit. Journal of Intensive Care Medicine 2003; 18: 29–41
- Venn M, Newman J, Grounds M. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Medicine 2003; 29: 201–207
- Bekker AY, Basile J, Gold M, Riles T, Adelman M, Cuff G, Mathew JP, Goldberg JD. Dexmedetomidine for awake carotid endarterectomy: Efficacy, hemodynamic profile, and side effects. Journal of Neurosurgical Anesthesiology 2004; 16: 126–135
- Willigers HM, Prinzen FW, Roekaerts PM. Comparison of the effects of dexmedetomidine and esmolol on myocardial oxygen consumption in dogs. European Journal of Anaesthesiology 2004; 21: 957–966
- Coursin DB, Coursin DB, Maccioli GA. Dexmedetomidine. Current Opinions in Critical Care 2001; 7: 221–226
- Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 2000; 93: 382–394
- Zornow MH, Scheller MS, Sheehan PB, Strnat MA, Matsumoto M. Intracranial pressure effects of dexmedetomidine in rabbits. Anesthesia and Analgesia 1992; 75: 232–237
- Zornow MH. Ventilatory, hemodynamic and sedative effects of the alpha 2 adrenergic agonist, dexmedetomidine. Neuropharmacology 1991; 30: 1065–1071
- Ard JL, Jr, Bekker AY, Doyle WK. Dexmedetomidine in awake craniotomy: A technical note. Surgical Neurology 2005; 63: 114–116, discussion 166–167
- Bloom M, Beric A, Bekker A. Dexmedetomidine infusion and somatosensory evoked potentials. Journal of Neurosurgical Anesthesiology 2001; 13: 320–322
- Mack PF, Perrine K, Kobylarz E, Schwartz TH, Lien CA. Dexmedetomidine and neurocognitive testing in awake craniotomy. Journal of Neurosurgical Anesthesiology 2004; 16: 20–25